Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. Ocumension Therapeutics invested …
( read original story …)

---